Pharmaceutical composition for preventing or treating angioedema, containing extract of peony root or mixture of peony root and licorice as active ingredient

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating angioedema, containing as an active ingredient a peony root extract or an extract of a mixture of peony root and licorice. In particular, the extract of a mixture of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, which may cause macular degeneration, inhibits blood-retinal barrier breakdown causing retinal edema in various animal models, protects or treats a subretinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema, or varicose veins.

Description

RELATED APPLICATIONS[0001]This application is a National Phase of PCT Patent Application No. PCT / KR2015 / 005116 having International filing date of May 21, 2015, which claims the benefit of priority of Korean Patent Application No. 10-2014-0062201 filed on May 23, 2014. The contents of the above applications are all incorporated by reference as if fully set forth herein in their entirety.FIELD AND BACKGROUND OF THE INVENTION[0002]The present invention relates to a composition for preventing or treating angioedema, such as retinal edema, macular degeneration, and varicose veins, containing an extract of peony root or a mixed extract of peony root and licorice as an active ingredient.[0003]Angioedema is referred to as a disease that due to the increased permeability of blood vessels in the deepest recesses of skin or under skin, or beneath mucous membranes fluids flow out from the blood vessels and pool in surrounding tissues (i.e. edema is caused), and occurs well in relatively loose ...

AI Technical Summary

Benefits of technology

[0015]It is an object of the present invention to provide a composition for preventing and treating angioedema containing a peony root extract, or a mixed extract of peony root and licorice as an active ingredient.

[0017]In addition, the present invention provides a health functional food for preventing and ameliorating angioedema containing a peony root extract, or a mixed extract of peony root and licorice as an active ingredient.

[0021]In addition, the present invention provides a use of a peony root extract, or a mixed extract of peony root and licorice for use as a health functional food for preventing and ameliorating angioedema.

[0022]The peony root extract, or the mixed extract of peony root and licorice according to the present invention inhibits the excessive generation of advanced glycation end products, inhibits breakdown of blood-retinal barriers causing retinal edema in various animal models, protects or treats a sub-retinal region causing dry macular degeneration, inhibits angiogenesis causing wet macular degeneration, and thus can be usefully used as an active ingredient for the composition for preventing and treating angioedema including macular degeneration, macular edema, retinal edema or varicose veins.

Problems solved by technology

Besides, obesity, and excessive intake of antioxidants and dietary fats also cause macular degeneration and influence to further progress.

But most seriously, there is no macular degeneration therapeutic agent.

Lucentis from Novartis, Switzerland, is an antibody therapeutic agent and very expensive, and it is impossible to stop the disease progression to such an extent as to restore sight.

However, if advanced glycation end products are excessively accumulated, the expression and secretion of cystatin C proteins are lowered to cause an imbalance of proteolytic action in the RPE basal portion, so that the macular degeneration occurs (IOVS, 2014, 55 (2), 926-34).

However, if the VEGF secretion is not strictly regulated, this acts as a critical factor leading to the terminal stage of macular degeneration.

Furthermore, it is a well-known fact that they do not completely control this.

Images